10-10-2017Print
East Coast, USA, protease inhibitor specialist KalVista Pharmaceuticals (Nasdaq: KALV) has signed a deal with Merck & Co (NYSE: MRK), sending shares in the thinly-traded startup through the roof.
Under the terms of the deal, Merck will pay $37 million upfront, and there is a potential for some $700 million or more in milestone payments and royalties, if all goes well.
Merck will acquire a near-10% stake in the firm, which saw its share price double…
This article is accessible to registered users, to continue reading pleaseregister for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.
Free
7 day trial access
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
£820
or £77 per month
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
Chairman, Sanofi Aventis UK
DealsKalVista PharmaceuticalsKVD001LicensingMerck & CoOphthalmicsPharmaceuticalResearchUSA
